M&A: INNOVATIVE MEDTECH, INC.

Form Type: 8-K

Filing Date: 2025-01-08

Corporate Action: Acquisition

Type: New

Accession Number: 000147793225000110

Comments: On December 17, 2024, Innovative MedTech, Inc. issued 6,500,000 shares of common stock to Red Halo, LLC, settling accrued compensation of $325,000 owed to CEO Michael Friedman. The issuance relied on the exemption under Section 4(a)(2) of the Securities Act, indicating no public offering involved. The company plans to enter the advanced wound care market, having signed consulting agreements with specialists to manage this expansion, utilizing biological amnionic membrane allograft technology. The company aims to introduce these services to its Sarah Care subsidiary and seek partnerships in wound care, targeting a market projected to grow substantially. Furthermore, on January 5, 2025, the company signed an Asset Purchase Agreement with AI Health Technologies, Inc. to acquire their CyberHealthAI system, designed to enhance healthcare procedures. This acquisition is under due diligence and not binding until completion. Additionally, IMTH has entered a Memorandum of Understanding with Texas A&M College of Dentistry to conduct a bioequivalence study for its Oral Thrush medication, following an Exclusive License Agreement that grants IMTH 80% ownership of the distribution subsidiary for this product. The global oral candidiasis treatment market is also projected to grow significantly.

Document Link: View Document

Form Type: 8-K/A

Filing Date: 2025-01-08

Corporate Action: Acquisition

Type: Update

Accession Number: 000147793225000114

Comments: Innovative MedTech, Inc. filed an amended Form 8-K/A to correct details from a previous report dated January 17, 2025. The amendment includes information about the issuance of 6,500,000 shares of common stock valued at $325,000 to Red Halo, LLC, to settle accrued compensation owed to CEO Michael Friedman, executed under the exemption from registration per Section 4(a)(2) and/or Rule 506(b) of the Securities Act of 1933. Furthermore, in the report, IMTH announces its strategic plans to enter the advanced wound care market by signing consulting agreements with leaders in wound care and aims to leverage a unique biological amnionic membrane allograft. Additionally, it reveals the recent signing of an Asset Purchase Agreement (APA) to acquire the CyberHealthAI system from AI Health Technologies, which promises improved healthcare service delivery, with sales and licensing expected to commence in Q2 2025, contingent on due diligence completion. The report also discusses a Memorandum of Understanding with Texas A&M College of Dentistry for a bioequivalence study related to an oral thrush treatment, projecting growth in the associated market over the next several years.

Document Link: View Document